Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

From 1964 to 1987, the EORTC Lymphoma Group conducted four consecutive controlled clinical trials on clinical stages I and II Hodgkin's disease in which 1,579 patients were entered. From the onset the main aim of these trials was to identify the subsets of patients who could be treated safely by regional radiotherapy (RT). Therefore, several prognostic indicators were prospectively registered and progressively used in the trial protocols for the delineation of the favorable and unfavorable subgroups as soon as they were recognized of high predictive value. In the H2 trial (1972 to 1976), the histologic subtype was the only variable taken into account for the therapeutic strategy and the staging laparotomy findings were found to be of prognostic value only in patients with favorable prognostic indicators. In the H5 trial (1977 to 1982), patients were subdivided into two subgroups according to six prognostic indicators. Patients with favorable features were submitted to a staging laparotomy (lap); lap negative patients were randomized between mantle field RT and mantle field plus paraaortic RT. Disease free survival (DFS) and total survival (S) were similar in the two arms. Among patients with unfavorable features, DFS and S were significantly higher in the arm treated by combination of mechlorethamine, vincristine, procarbazine, prednisone (MOPP) chemotherapy (CT) and RT than in the arm treated by total nodal irradiation. Nevertheless, in patients below the age of 40, the overall survival rates were equivalent in the two arms. In the H6 trial, the delineation of the favorable subgroup was based on (a) absence of systemic symptoms and elevated ESR, (b) no more than one or two lymph node areas involved. The aim of the study was to assess the impact on survival of a therapeutic strategy including staging laparotomy. At a 4-year follow-up, no difference in survival was evidenced. In patients with unfavorable prognostic indicators, 3 MOPP-RT-3 MOPP were compared with 3 ABVD-RT-3 ABVD. From H1 to H5 trials, the proportion of patients having received CT during the course of the disease gradually decreased; the data suggest that a further reduction in the proportion of patients aggressively treated is conceptually possible. On the basis of the prognostic factors identified, one can delineate three subsets of patients and modulate toxic cost of the initial treatment according to the characteristics of these subsets. In the most favorable subgroup, RT alone produces high survival and CT is not justified.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  D. Green,et al.  The effect of mediastinal irradiation on cardiac function of patients treated during childhood and adolescence for Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Rosenberg The role of chemotherapy in the management of early stage Hodgkin's disease , 1984, Hematological oncology.

[3]  M. Tubiana,et al.  The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. , 1984, International journal of radiation oncology, biology, physics.

[4]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[5]  M. Tubiana,et al.  Renal consequences of irradiation of the spleen in lymphoma patients. , 1979, The British journal of radiology.

[6]  M Pagano,et al.  Corrected group prognostic curves and summary statistics. , 1982, Journal of chronic diseases.

[7]  N. Day,et al.  Second malignancies following testicular cancer, ovarian cancer and hodgkin's disease: An international collaborative study among cancer registries , 1987, International journal of cancer.

[8]  E. Jaffe,et al.  Twenty years of MOPP therapy for Hodgkin's disease. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Kaplan,et al.  The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. , 1984, International journal of radiation oncology, biology, physics.

[10]  W. Velasquez,et al.  Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Henry-Amar Quantitative risk of second cancer in patients in first complete remission from early stages of Hodgkin's disease. , 1988, NCI monographs : a publication of the National Cancer Institute.

[12]  M. Tubiana,et al.  A multivariate analysis of prognostic factors in early stage Hodgkin's disease. , 1985, International journal of radiation oncology, biology, physics.

[13]  Flavio Crippa,et al.  Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Cosset,et al.  Radiation injuries of the gastrointestinal tract in Hodgkin's disease: the role of exploratory laparotomy and fractionation. A study of 19 cases observed in a series of 134 patients treated at the Institut Gustave Roussy from 1972 to 1982. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  K. Maclennan,et al.  REVIEW OF BRITISH NATIONAL LYMPHOMA INVESTIGATION STUDIES OF HODGKIN'S DISEASE AND DEVELOPMENT OF PROGNOSTIC INDEX , 1985, The Lancet.

[16]  M. Tubiana,et al.  Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[17]  M. Gospodarowicz,et al.  Results of treating Hodgkin's disease without a policy of laparotomy staging. , 1982, Cancer treatment reports.

[18]  M. Tubiana,et al.  Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease , 1984, Cancer.

[19]  P. Siltanen,et al.  Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin's disease , 1987, Cancer.

[20]  M. Tubiana,et al.  The contribution of clinical trials to the treatment of patients with early stages of Hodgkin's disease. , 1986, Drugs under experimental and clinical research.

[21]  S. Rosenberg Exploratory laparotomy and splenectomy for Hodgkin's disease: a commentary. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Tubiana,et al.  Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Tucker,et al.  Risk of second cancers after treatment for Hodgkin's disease. , 1988, The New England journal of medicine.

[24]  H. Hansen,et al.  RISK OF THERAPY-RELATED LEUKAEMIA AND PRELEUKAEMIA AFTER HODGKIN'S DISEASE Relation to Age, Cumulative Dose of Alkylating Agents, and Time from Chemotherapy , 1987, The Lancet.

[25]  A. Horwich,et al.  An analysis of prognostic factors in early stage Hodgkin's disease. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  M. Tubiana,et al.  EORTC Lymphoma Cooperative Group studies in clinical stage I-II Hodgkin's disease 1963-1987. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[27]  T. Lister,et al.  Prognostic factors in lymphoma , 1987 .

[28]  S. Hellman,et al.  Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease. , 1982, Cancer treatment reports.

[29]  M. Gospodarowicz,et al.  Prognostic groups for management of localized Hodgkin's disease. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Tubiana,et al.  The prognostic significance of large mediastinal masses in the treatment of Hodgkin's disease. The experience of the institut gustave‐roussy , 1984, Hematological oncology.

[31]  E. Gehan,et al.  Reporting outcomes in Hodgkin's disease and lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Bloomfield,et al.  Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy. , 1987, International journal of radiation oncology, biology, physics.

[33]  C. Haanen,et al.  Major complications and causes of death in patients treated for Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Noordijk,et al.  Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Horning,et al.  Female Reproductive Potential after Treatment for Hodgkin's Disease , 1981, The New England journal of medicine.

[36]  M. Wartelle,et al.  PIGAS - An Interactive Statistical Database Management System , 1983, SSDBM.

[37]  D. Cox Regression Models and Life-Tables , 1972 .